Stockreport

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

Ovid Therapeutics Inc.  (OVID) 
Last ovid therapeutics inc. earnings: 3/11 08:00 am Check Earnings Report
US:NASDAQ Investor Relations: investors.ovidrx.com
PDF OV350 showed a good safety profile, supporting the advancement of the Company’s KCC2 portfolio, including the first oral direct activator, OV4071There were no treatment- [Read more]